Skip to content
OpenCapital
Get started

MBX Biosciences, Inc. MBX Q1 2026 earnings

Reported May 7, 2026 · Before market open

Diluted EPS-$0.51Beat by $0.11
EPS estimate-$0.62

Next report

Aug 6, 2026 (in a month)
EPS estimate-$0.68

Financials

Q1 2026

Income statement

See full
Operating income-$27.3M-2.8%
Net income-$23.5M+1.5%
EPS (diluted)-$0.50+29.6%

Balance sheet

See full
Cash & equivalents$45.2M+51.2%
Total debt$555.0K+327%
Total equity$437.8M+85.9%
Total assets$452.7M+84.1%

Cash flow

See full
Operating cash flow-$20.2M+10.9%
CapEx$437.0K+1,357%
Free cash flow-$20.6M+9.1%

Valuation & ratios

Valuation

as of 06/24/26
See full
Market cap$2.21B+475%
Enterprise value$2.16B+533%

Returns & leverage

See full
Return on equity-25.7%—
Debt / equity0×0.0×
Current ratio30.8×+7.5×

Versus estimates

Diluted EPS

Q1 2026-$0.51Beat by $0.11
Q4 2025-$0.49Beat by $0.15Q3 2025-$0.63Beat by $0.10Q2 2025-$0.58Beat by $0.19Q1 2025-$0.71Beat by $0.10Q4 2024-$0.47Beat by $0.12

Ask the moment MBX Biosciences, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did MBX Biosciences, Inc. report Q1 2026 earnings?
MBX Biosciences, Inc. (MBX) reported Q1 2026 earnings on May 7, 2026 before market open.
What were MBX Biosciences, Inc.'s Q1 2026 revenue and EPS?
MBX Biosciences, Inc. reported diluted EPS of $-0.51 for Q1 2026.
Did MBX Biosciences, Inc. beat estimates in Q1 2026?
EPS beat the consensus estimate of $-0.62 by $0.11.
How did MBX Biosciences, Inc.'s Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, diluted EPS grew 28.2% from $-0.71.
Where can I find MBX Biosciences, Inc.'s Q1 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-210825) and the 10-Q periodic report (0001193125-26-210593) directly on SEC EDGAR. The filing index links above go to sec.gov.